Kodiak Sciences Inc. (KOD) |
|
4.725 -0.165 (-3.37%)
|
03-24 12:38 |
|
Open: |
4.8 |
Pre. Close: |
4.89 |
|
High:
|
4.85 |
Low:
|
4.62 |
|
Volume:
|
254,619 |
Market Cap:
|
247(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 12:02:18 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 7.47 One year: 8.76 |
| Support: |
Support1: 4.61 Support2: 3.84 |
| Resistance: |
Resistance1: 6.39 Resistance2: 7.5 |
| Pivot: |
5.56 |
| Moving Average: |
MA(5): 4.96 MA(20): 5.79
MA(100): 7.13 MA(250): 7.78 |
| MACD: |
MACD(12,26): -0.7 Signal(9): -0.6 |
| Stochastic oscillator: |
%K(14,3): 3.3 %D(3): 6.6 |
| RSI: |
RSI(14): 23.4 |
| 52-week: |
High: 12.8 Low: 4.61 |
| Average Vol(K): |
3-Month: 272 (K) 10-Days: 442 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KOD ] has closed above bottom band by 11.7%. Bollinger Bands are 59.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.17 - 5.2 |
5.2 - 5.23 |
|
Low:
|
4.73 - 4.76 |
4.76 - 4.8 |
|
Close:
|
4.83 - 4.89 |
4.89 - 4.94 |
|
Company Description |
|
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. |
Headline News |
Wed, 22 Mar 2023
Daily Markets: Sentiment Rebounds After JPMorgan (JPM) Shores Up First Republic - Nasdaq
Mon, 20 Mar 2023
North American Morning Briefing: Banking Sector -2- - Marketscreener.com
Fri, 17 Mar 2023
How Does Kodiak Sciences Inc (KOD) Stock Rank on Wall Street Friday? - InvestorsObserver
Fri, 10 Mar 2023
Federated Hermes Inc. Buys 246353 Shares of Kodiak Sciences Inc ... - MarketBeat
Thu, 09 Feb 2023
Kodiak Sciences Inc. (NASDAQ:KOD) insiders who sold US$12m worth of stock earlier this year are probably glad they did so as market cap slides to US$384m - Simply Wall St
Fri, 03 Feb 2023
BlackRock Increases Position in Kodiak Sciences (KOD) - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
52 (M) |
| Shares Float |
32 (M) |
|
% Held by Insiders
|
5.6 (%) |
|
% Held by Institutions
|
82 (%) |
|
Shares Short
|
1,550 (K) |
|
Shares Short P.Month
|
1,500 (K) |
Stock Financials |
|
EPS
|
-2.92 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
16.95 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-26.8 |
|
Return on Equity (ttm)
|
-59.2 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-6.85 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-210 (M) |
|
Levered Free Cash Flow
|
-157 (M) |
Stock Valuations |
|
PE Ratio
|
-1.62 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.27 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.17 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
